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The antiviral properties of broadly neutralizing antibodies against HIV are
well-documented but no vaccine is currently able to elicit protective titers of
these responses in primates. While current vaccine modalities can readily induce
non-neutralizing antibodies against simian immunodeficiency virus (SIV) and HIV,
the ability of these responses to restrict lentivirus transmission and replication remains
controversial. Here, we investigated the antiviral properties of non-neutralizing antibodies
in a group of Indian rhesus macaques (RMs) that were vaccinated with vif, rev, tat, nef,
and env, as part of a previous study conducted by our group. These animals manifested
rapid and durable control of viral replication to below detection limits shortly after
SIVmac239 infection. Although these animals had no serological neutralizing activity
against SIVmac239 prior to infection, their pre-challenge titers of Env-binding antibodies
correlated with control of viral replication. To assess the contribution of anti-Env humoral
immune responses to virologic control in two of these animals, we transiently depleted
their circulating antibodies via extracorporeal plasma immunoadsorption and inhibition
of IgG recycling through antibody-mediated blockade of the neonatal Fc receptor.
These procedures reduced Ig serum concentrations by up to 80% and temporarily
induced SIVmac239 replication in these animals. Next, we transferred purified total Ig
from the rapid controllers into six vaccinated RMs one day before intrarectal challenge
with SIVmac239. Although recipients of the hyperimmune anti-SIV Ig fraction were not
protected from infection, their peak and chronic phase viral loads were significantly lower
than those in concurrent unvaccinated control animals. Together, our results suggest
that non-neutralizing Abs may play a role in the suppression of SIVmac239 viremia.
Keywords: non-neutralizing antibodies, SIV, rhesus macaques (Macaca mulatta), immunoadsorption, anti-FcRn
Ab, adoptive transfer, antibody depletion
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INTRODUCTION
Antibodies (Abs) are one of the two major components of the
adaptive immune response and are key in vaccine development.
Indeed, vaccine efficacy is primarily contingent upon the
generation of Abs that protect against infection. Protective Abs
mediate pathogen control and clearance by neutralization and
Fc effector functions. In some cases, however, pathogen-specific
Abs can enhance disease, as seen during re-infection with dengue
virus (1, 2).
The development of an HIV vaccine capable of eliciting
protective Abs remains one of the highest priorities of the
HIV/AIDS research effort. While neutralizing Abs can prevent
infection and suppress HIV/SIV replication in humans and
Indian rhesus macaques (RMs), high levels of neutralizing Ab
titers against a neutralization resistant tier 3 virus not yet
been induced by vaccination. However, nearly all individuals
produce non-neutralizing Abs after infection with HIV, and
many vaccination regimens have induced such non-neutralizing,
Env-binding Abs. The scientific community is still evaluating the
role of non-neutralizing Abs in HIV/SIV infection. The results
of adenovirus 26 (Ad26) vaccination and transfer studies in
RMs (3–5) suggested the potential benefit that non-neutralizing
Env-binding Abs might have against HIV/SIV. Interestingly,
protection in Ad26-vaccinated RMs was associated with the
induction of polyfunctional Abs with the capacity to mediate Fc
effector functions, including Ab-dependent cellular cytotoxicity
(ADCC), Ab-dependent cellular phagocytosis (ADCP), and Ab-
dependent complement deposition (ADCD) (3, 4).
Control of HIV/SIV replication after infection has been
previously described. Some HIV-infected individuals and
SIV-infected RMs expressing certain major histocompatibility
complex class I (MHC-I) alleles spontaneously control viremia
during early chronic infection in the absence of antiretroviral
therapy. Recently, we reported an unusual group of immunized
Mamu-B∗17+ RMs that manifested stringent control of the
highly pathogenic SIVmac239 infectious molecular clone after
being vaccinated with vif, nef and env (6). While around 20% of
unvaccinated Mamu-B∗17+ RMs naturally control SIVmac239
replication, it usually takes 12–20 weeks to reduce viral loads
below 1,000 viral RNA (vRNA) copies/ml (7). In this study,
five of the eight env-vaccinated Mamu-B∗17+ RMs suppressed
viral replication to undetectable levels (<15 vRNA copies/ml)
by 4–8 weeks post-infection. Remarkably, Mamu-B∗17+
RMs vaccinated with vif and nef only (without env) did not
exhibit this stringent level of control of SIVmac239 replication,
implicating vaccine-induced Env-specific immune responses in
control of replication (6). Indeed, control was associated with
high endpoint titers of vaccine-induced gp140-binding Abs on
day of challenge. Interestingly, these vaccine-induced Abs did
not neutralize SIVmac239, and serum ADCC activity did not
correlate with control. This level of control resembled the rapid
and profound control of SIVmac239 replication manifested by
RMs vaccinated with the 68-1 rhesus cytomegalovirus (rhCMV)
expressing SIV proteins (8–10).
To further investigate the mechanism of virologic control in
our Mamu-B∗17+ rapid controllers, we designed a multifaceted
study aimed at determining the relative contribution of vaccine-
elicited non-neutralizing Abs to the rapid viremic control
observed in this unique RM cohort. Using systems serology (11),
we first characterized the functional properties of these vaccine-
elicited Env-binding Abs. To determine if these Abs contributed
to suppression of viral replication, we monitored viral loads
of two Mamu-B∗17+ rapid controllers with viral loads below
limits of detection after isolating and depleting circulating Abs by
immunoadsorption and administration of a neonatal Fc receptor
(FcRn)-blocking Ab. Finally, we evaluated the efficacy of these
Abs in vivo by administering the purified immunoglobulin (Ig)
from the two rapid controllers to six vaccinated RMs 1 day
prior to intrarectal SIVmac239 challenge. Collectively, our data
suggest that non-neutralizing Abs may contribute to control of
SIVmac239 replication in vivo.
RESULTS
Characterization of Circulating
SIVmac239-Specific Abs in Immunized
Mamu-B∗17+ Indian Rhesus Macaques
To identify a shared Ab signature among the five vaccinated
rapid controllers from our previous vaccine trial, we assessed
the vaccine-induced Ab responses developed in each animal at
the time of the first challenge by systems serology (12). We
had previously determined SIVmac239 neutralization titers and
ADCC activity in these animals (6). Here, we analyzed Ab
titers, FcγR affinity, and assessed three Fc-mediated effector
functions: ADCP, NK cell degranulation, and ADCD (Figure 1).
Because all Fc effector function assays were performed using
human cells, rather than rhesus, we first confirmed that these
circulating Abs bound human FcγRIIa, FcγRIIb, and FcγRIIIa
(Supplementary Figure 1). In the group of eight Env-vaccinated
Mamu-B∗17+ animals, we compared RMs that showed stringent
control (n = 5) to those that did not (n = 3). Rapid controllers
had slightly higher total IgG and IgG1 serum concentrations
of Abs targeting SIV gp140, although this difference was not
statistically significant. These Env-specific Abs also exhibited
a higher affinity for rhesus FcγRIIa and FcγRIIIa relative to
non-controllers (Figure 1A), which was also not statistically
significant. Since Barouch et al. reported that protected Ad26-
vaccinated RMs had developed highly polyfunctional Abs (3), we
evaluated the capacity of our vaccine-induced Abs to mediate
ADCP, ADCD and NK cell activation (Figure 1B). While we
detected enhanced ADCD and NK cell degranulation activity
(using staining for CD107a) mediated by the gp140-binding Abs
present in the serum of the rapid controllers at day of challenge,
these differences were not statistically significant.
Isolation and Depletion of Circulating IgG
by Immunoadsorption
Next, we explored the hypothesis that the stringent viremic
control observed in our previous vaccine trial was mediated
by vaccine-induced Abs. We evaluated the ability of these Abs
to facilitate control of viral replication in vaccinated animals
and whether depletion of these Abs in the stringent controller
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FIGURE 1 | Characterization of Env-binding Abs from Mamu-B*17+ RMs at the time of first SIV challenge. Sera of immunized Mamu-B*17+ rapid controllers (in
green) were compared to sera of non-controllers (in pink) prior to challenge at 1:500 dilution. (A) gp140-specific Ab subclass and isotype titers, and rhesus
FcγRIIa/FcγRIIIa affinity were measured by Luminex. Mean log MFI for negative controls was 3.7. (B) gp140-specific responses for each of the three Ab effector
functions measured: ADCP, ADCD, and NK degranulation. None of the differences between rapid controllers and non-controllers at the time of SIV challenge from
both panels were statistically significant (p > 0.05 by Mann-Whitney U test).
Mamu-B∗17+ RMs would result in viral rebound. While it
is possible to isolate Ig from serum or plasma by collecting
blood draws, the monthly blood available is limited by the
weight of each animal. Thus, to overcome this restriction and
isolate sufficient Ig to eventually transfer it to another set of
vaccinated animals, we subjected r05007 and r09062, the two
rapid controllers with the highest Env-specific Ab titers, to
at least four rounds of therapeutic plasma exchange with a
secondary plasma device using the Spectra Optia system (Terumo
BCT) (13). This method has been previously used to remove
circulating immunocomplexes and pathological auto-Abs in
circulation (14–18). In contrast to plasmapheresis or standard
therapeutic plasma exchange, where plasma is removed and
replaced with fluids containing albumin and coagulation factors,
we employed a continuous-flow centrifugation procedure, also
known as immunoadsorption, to selectively remove Ig from
plasma before reinfusing the Ig-depleted plasma back into the
same animal. Immunoadsorption minimizes the side effects
usually associated with plasmapheresis and allowed us to run
one liter of plasma, corresponding to 2.5 times the animal’s total
blood volume, through four protein A or protein G columns.
Using this technique, we isolated 15 g of total Ig from r05007 and
r09062 over 3 months. After each round of immunoadsorption,
IgG levels in both RMs were reduced by 53–76% compared to
baseline (defined as the serum IgG concentration before each
procedure) (Figures 2A,B). Additionally, we monitored the viral
loads of these animals. At the time of the first procedure, both
RMs were suppressing viral replication to <15 vRNA copies/ml
(Figures 2A,B). Seven days after the first immunoadsorption,
r05007 had a viral load of 650 vRNA copies/ml, and on day 14,
viremia peaked at 940 vRNA copies/ml (Figure 2A). Viral loads
in r05007 fluctuated between 15 and 940 vRNA copies/ml during
all five rounds. r09062 maintained undetectable viral loads, <15
vRNA copies/ml, throughout all four procedures (Figure 2B).
Thus, the temporary reduction of circulating Abs caused by
immunoadsorption led to a transient rebound in SIV replication.
Anti-neonatal FcR Ab Treatment Depletes
Plasma IgG in RMs
FcRn has been described as the main factor responsible for
prolonging IgG half-life by protecting it from the lysosomal
degradative pathway (19–22). IgG recycling is possible because
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the FcRn binds to the Fc portion of IgG with high affinity at
low pH, but not at neutral pH (23, 24). The pH dependence
of the FcRn-IgG interaction facilitates the translocation of IgG
from acidic endosomes to the cell surface, then its subsequent
release into the near-neutral pH of circulation. Hence, it is not
surprising that in vivo FcRn dysfunction has been linked to
low plasma IgG concentrations (25). Recently, Smith et al. used
Rozanolixizumab, an anti-FcRn monoclonal Ab, to safely and
efficiently block FcRn and deplete circulating IgG in cynomolgus
macaques (26). With this in mind, we reasoned that a prolonged
reduction in IgG levels would result in loss of viremic control if
the non-neutralizing Abs circulating in the Mamu-B∗17+ rapid
controllers had a role in suppressing SIVmac239 replication. We
administered a simianized Rozanolixizumab chimera (anti-FcRn
rhIgG1 [RozR1LALA]) to the two rapid controllers. Monkey
r05007 received an intravenous dose of 30 mg/kg followed by
a subcutaneous daily dose of 5 mg/kg for 1 week, while r09062
received a single intravenous dose of 300 mg/kg. We then
quantified circulating IgG and SIVmac239 viral loads. r05007
received the anti-FcRn Ab infusion two days after the last round
FIGURE 2 | IgG levels and viral loads after the removal of circulating Abs from
r05007 and r09062. Ig depletion by immunoadsorption and anti-FcRn Ab
infusion of (A) r05007 and (B) r09062. Gray arrows indicate each
immunoadsorption procedure. The blue dashed arrow indicates the first
anti-FcRn Ab infusion. Viral load limit of detection (LOD) is shown as purple
dotted line.
of immunoadsorption. At the time of the first anti-FcRn Ab
administration, the IgG concentration in this animal was already
reduced by 45.8% relative to baseline, and viremia had increased
from 500 to 790 vRNA copies/ml. Three days after commencing
Ab infusion, viral loads peaked at 1,700 vRNA copies/ml.
Maximal IgG depletion, an 80.3% decrease relative to baseline,
was observed 10 days following the first infusion (or three days
after the final subcutaneous dose) (Figure 2A). Unlike r05007,
r09062 controlled viral replication throughout all four rounds of
immunoadsorption. Although these two Mamu-B∗17+ animals
had been infected for over five years (Supplementary Figure 2),
r09062 had maintained viral loads below detection limits for
over 4.5 years (Supplementary Figure 2B). Two weeks after
the last immunoadsorption, r09062 received a single infusion
of anti-FcRn Ab and its IgG levels started to decrease. One
week later, IgG levels were reduced 73.9% relative to baseline
(Figure 2B). Viral loads remained <15 vRNA copies/ml for 27
days after the anti-FcRn Ab administration. We then started
to observe plasma viral “blips” ranging from 15 to 25 vRNA
copies/ml over the following 100 days. It should be noted that
both animals developed moderate titers of anti-drug Abs after
treatment with anti-FcRn Ab, independent of the infusion route
and dose (Supplementary Figure 3).
Ig Characterization and Passive Transfer
Study
To further investigate the virologic control observed in the
Mamu-B∗17+ RMs of our previous vaccine trial, six RMs
expressing Mamu-A∗01+ and/or Mamu-A∗02+ MHC-I alleles
(Table 1) were vaccinated with gag, nef, tat, rev, vif, vpr, and
vpx. SIV genes were delivered using a recombinant vesicular
stomatitis virus (rVSV) prime followed by a recombinant
adenovirus type 5 (rAd5) boost. Both vaccine vectors utilized
in this study included gag, tat and nef, or tat fused with other










Rapid controllers r05007 Mamu-B*17 15 Female
r09062 Mamu-B*17 10.5 Female
Group 1
(Vaccinees)
r15088 Mamu-A*01, -A*02 4.7 Male
r16013 Mamu-A*02 4.4 Male
r15033 Mamu-A*02 5.0 Male
r15043 Mamu-A*01 4.9 Female
r15010 Mamu-A*02, -B*17 5.5 Male
r14126 Mamu-A*01, -A*02 5.7 Male
Group 2 (Controls) r16101 Mamu-A*01 3.8 Male
r17027 Mamu-A*01 3.2 Male
r17074 Mamu-A*01 2.9 Male
r16066 Mamu-A*02 4.1 Male
r16099 Mamu-A*02 3.8 Female
r05085 Mamu-A*02 14.8 Female
*Animal age at the beginning of the study.
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genes (i.e., vif, vpr, vpx, and rev) but did not include env. As
a reference, our Mamu-B∗17+ cohort was vaccinated with env,
vif, nef, tat, and rev, which were delivered using a recombinant
yellow fever virus 17D prime followed by three boosts with
recombinant DNA plasmids delivered by electroporation (6).
These animals were then administered rAd5, rVSV and rhesus
monkey rhadinovirus (rRRV) constructs, and were challenged
almost 4 months after the last rRRV boost. At the time of the
first SIV challenge, we detected SIV-specific T cell responses
by intracellular cytokine staining (ICS) in the peripheral blood
mononuclear cells (PBMCs). These animals had developed
vaccine-induced CD8+ T cells mainly directed against vif and
nef, and CD4+ T cells against env. Conversely, we were unable
to detect SIV-specific T cell responses, by ICS, in the PBMCs
of our Group 1 vaccinees at the time of the first intrarectal SIV
challenge (data not shown), which was 2 years after the rAd5
boost. One day before the first SIV challenge, all vaccinated RMs
(Group 1) received 200 mg/kg of the purified Ig derived from
the two Mamu-B∗17+ vaccinated animals. A large proportion
of the infused Ig targeted SIV Env (Figure 3). At the time of
SIV challenge, detectable levels of Env-binding Abs were present
in all recipient RMs. Ab levels were comparable among all
Group 1 animals and ranged from 221 to 321µg/ml of gp140-
specific IgG in circulation (Table 2). No neutralization activity
against SIVmac239 was detected in the purified total Ig (data not
shown).We evaluated the contribution of these Abs to protection
against acquisition and suppression of viremia post-infection
by subjecting all animals to six repeated intrarectal challenges
with a marginal infectious dose of SIVmac239, as previously
described (27), starting one day following the Ig passive transfer.
Six additional unvaccinated, non-Ig-infused RMs expressing
FIGURE 3 | Total and Env-specific binding Abs present in the purified total Ig
isolated from the Mamu-B*17+ RMs at 1µg/ml. At a normalized
concentration of 1µg/ml, a large proportion of Abs present in the purified total
IgG bound to SIVmac239 gp140 protein. The purified total Ig had no
neutralization activity against SIVmac239 (data not shown).
Mamu-A∗01+ and/or Mamu-A∗02+ MHC-I alleles (Group 2)
served as controls for this challenge experiment (Table 1). In
Group 1, Env-specific Ab titers decreased by 35% during the
first week after infusion and continued to decline until the sixth
challenge. Eleven weeks later, we detected 2.25µg/ml of gp140-
specific Abs in r15010, the only RM from Group 1 that remained
uninfected after six SIVmac239 challenges (Table 2). Of note,
r15010 was the only RM in Group 1 or 2 that also expressed
the elite control-associatedMamu-B∗17+ allele (Table 1).We did
not observe any correlation between the level of Env-binding Abs
in the sera of the Group 1 vaccinees and the rate of SIVmac239
acquisition. Although vaccinees and control animals acquired
SIV at similar rates (Figure 4A), Group 1 exhibited significantly
lower peak (P = 0.0079) and chronic phase viral loads (P
= 0.0317) (Figures 4B–D). The difference in geometric mean
viremia between both groups was also statistically significant (P
= 0.0003) (Figure 4E). Collectively, these data suggest that non-
neutralizing Abs may contribute to suppression of SIVmac239
replication in vivo.
DISCUSSION
In this study, we assessed the potential role of vaccine-elicited
non-neutralizing Abs in our Mamu-B∗17+ rapid controllers
in the prevention and control of SIV infection. First, we
characterized the functional profile of the vaccine-induced Abs
from our vaccinated Mamu-B∗17+ cohort, which demonstrated
stringent control of SIVmac239 replication (6). Next, we isolated
and depleted circulating Ig from two Mamu-B∗17+ rapid
controllers that suppressed viral replication to below detection
limits for an extended period of time. The removal of Ig from
serum of these two elite controllers resulted in transient low
levels of measurable viremia in both RMs. To determine whether
the hyperimmune anti-SIV Ig fraction isolated from the Mamu-
B∗17+ RMs could contribute to suppression of viral replication
in animals lacking elite control-associated MHC-I alleles, we
infused this pooled total Ig into six vaccinated RMs one day
TABLE 2 | Env-specific serum IgG (µg/ml) in Group 1 prior to infection.
Weeks after
Ig infusion
r15043 r16013 r14126 r15088 r15033 r15010 Average
0 258.65 263.26 318.87 221.24 321.13 302.54 280.95
1 145.27 107.95 272.92 198.31 181.11
2 54.04 64.09 83.00 80.06 70.30
3 53.50 66.59 60.05
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FIGURE 4 | Outcome of SIV challenge. Two years after vaccination, vaccinees and controls were intrarectally challenged with a low dose of SIVmac239. (A)
Kaplan-Meier analysis of SIV acquisition, (B) individual viral loads of Group 1 vaccinees (blue) and the Group 2 (red) RMs. While the difference in acquisition rate was
not statistically significant (p > 0.05 by log-rank test), (C) peak, and (D) setpoint viremia were significantly lower for vaccinees than controls (P = 0.0079 and P =
0.0317, respectively). Peak viral loads were defined as the highest viral load measurement within the first 4 weeks post-infection. Chronic phase setpoint was
calculated as the geometric mean of viral load values between 8 and 12 weeks post-infection. (E) Geometric mean viral loads for Group 1 and Group 2 animals (P =
0.0003). Of note, we did not identify any correlation between the level of Env-binding Abs on the challenge day and take of the infection. P-values were determined
using the Mann-Whitney U test.
before intrarectal SIVmac239 challenge. While passive transfer of
total Ig did not protect against infection, the vaccinees exhibited
significant reductions in peak and chronic phase viremia relative
to the control group. Overall, these data suggest that non-
neutralizing Abs may play a role in SIVmac239 suppression
in vivo.
Our previous analysis suggested that Env-specific non-
neutralizing Abs could contribute to the stringent control of
SIVmac239 observed in the Mamu-B∗17+ rapid controllers
(6). However, the mechanistic basis for rapid control remains
unknown. In the present study, we evaluated whether Fc-
mediated effector functions were involved in such stringent
suppression. Although none of these functions correlated with
rapid control, the Fc domain is known to engage a wide spectrum
of receptors on different cell types of the immune system.
Bournazos et al. recently evaluated the effect of FcγR binding
of influenza-specific Abs in protecting humanized mice against
lethal influenza challenge (28–30). Mice treated with these Abs
showed enhanced protection when the Fc region was modified to
engage FcγRIIa, alone or in combination with FcγRIIIa (31, 32).
Further, the authors did not observe antiviral protection in FcγR-
deficient mice treated with these influenza-specific Abs (33). It
remains possible that the mechanistic basis for rapid control in
Mamu-B∗17+ RMs involves binding of these non-neutralizing
Abs to FcγRs. Antigen-Ab immune complexes, for example,
could have elicited SIV-specific CD8+ T cell responses in those
animals via engagement of antigen-presenting cells, perhaps
driving dendritic cell maturation and antigen cross-presentation.
Mamu-B∗17+ RMs are naturally predisposed to
spontaneously control SIV infection without antiretroviral
therapy. Previous studies have implicated Mamu-B∗17-restricted
CTLs as the main contributors to elite control in these RMs
(6). However, the contribution of SIV-specific Abs to this
elite control is unclear. Recently, we vaccinated two groups
of Mamu-B∗17+ RMs with vif and nef, with and without the
addition of env. Interestingly, the group that received env, vif,
and nef showed unprecedented rapid control of SIVmac239 after
infection, highlighting the potential role of vaccine-induced,
non-neutralizing Abs in suppressing viremia. One of the many
advantages of the SIV-infected RM model is the ability to
determine the contribution of a particular cell type by depleting
it and measuring viral rebound (34–39). Currently, it is possible
to ablate cells in vivo by using depleting monoclonal Abs that
target a particular cell type. We and other groups have previously
depleted CD8β+ T cells and CD20+ cells with the anti-CD8β
Ab CD8β255R1 (38–40) and anti-CD20 Ab Rituximab (41–43),
respectively. Although Rituximab can efficiently deplete CD20+
cells from circulation and lymphoid tissue (42), Ab-secreting cells
in RMs have surface marker phenotypes that differ from those
of humans, making them challenging to identify and adequately
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deplete. Since there are no existing regimens for depletion
of Ab-secreting cells in RMs, we aimed to reduce levels of
circulating Abs in our SIV-infected Mamu-B∗17+ RMs through
two novel approaches: immunoadsorption and the infusion of an
anti-FcRn Ab. These strategies depleted up to 80% of serum Abs
in r05007 and r09062. Previous studies have demonstrated that
near-complete depletion of circulating CD8β+ T cells can permit
transient viral rebound in elite controllers (38, 39). Because we
were unable to completely deplete circulating Abs in our animals,
it is possible that the remaining Abs in circulation mitigated
viral rebound, thereby “masking” their potential involvement in
viremic suppression. These “blips” of transient viremia in both
Mamu-B∗17+ RMs suggest that the removal of Env-binding Abs
partially contributed to such control. However, since the total
amount of Abs in circulation regulates frequencies of activated
B cells and the total quantity of Ig produced through a quorum
sensing-like mechanism (44), our experimental interventions
may have resulted in inadvertent B cell activation and stimulation
of latently-infected CD4+ T cells in lymphoid follicles, thereby
resulting in the transient viremia observed in these animals.
Thus, we cannot definitively conclude that the depletion of
non-neutralizing Env-binding Abs from circulation directly
permitted viral rebound, and additional studies will be required
to determine the true efficacy of these Abs in suppressing viral
replication in vivo.
In this study, we attempted to determine whether vaccine-
induced Env-specific Abs could mediate stringent viremic
control in Mamu-B∗17-negative RMs. We passively transferred
purified Ig from two rapid controllers to six vaccinated RMs
that expressed the Mamu-A∗01+ and/or Mamu–A∗02+ MHC-
I alleles. We demonstrated that this vaccine regimen, along
with Ab infusion, resulted in statistically significant reductions
in both peak and chronic phase viral loads in the vaccinees.
Previously, we have shown that Mamu-A∗01+ and/or Mamu-
A∗02+ RMs immunized with nef, tat, vif, rev, and either
env, gag, or both, have significantly lower peak viral loads
than unvaccinated control animals (45). However, control of
chronic phase viremia was only observed in the group of
animals that were vaccinated with six of the viral genes (env,
gag, vif, rev, tat, and nef ). Notably, the vaccine-induced Abs
detected in these env-vaccinated animals did not neutralize
SIVmac239. All other groups failed to control chronic phase
viral replication. The animals in the present study were only
vaccinated with gag, vif, rev, tat, and nef (and not env), and
based on these previous results, would not be expected to
control chronic phase viremia. It can be presumed, therefore,
that Ig infusion of the Group 1 vaccinees resulted in better
control than might be expected in animals vaccinated with
only gag, vif, rev, tat, and nef. Interestingly, the RMs described
in this paper were challenged two years after vaccination and
had no detectable Gag-specific CD8+ T cells in their PBMCs.
Nevertheless, low levels of vaccine-induced Gag-specific CD8+
T cells (undetectable by ICS) could still be present in these
animals. These CD8+ T cells could have been stimulated by Ab
immune complexes and antigen-presenting cells after infection,
and then contribute to the suppression of SIVmac239 replication,
similarly to what could have occurred in our Mamu-B∗17+
rapid controllers.
Other groups have protected RMs from SIV and simian-
human immunodeficiency virus (SHIV) acquisition by
administering neutralizing Abs (46–49). Compared to non-
neutralizing Abs, neutralizing Abs have been shown to be
effective at low titers. Moldt et al. protected RMs against SHIV
after infusing 5 and 1 mg/kg of PGT121 (46), a potent broadly
neutralizing monoclonal Ab, one day before mucosal challenge.
Not surprisingly, the ability to neutralize the challenge virus
appears to be a key factor in preventing SIV/SHIV acquisition.
Neutralizing Abs can be present at much lower concentrations in
the target tissue and still be able to confer protection. Although
the purified Ig was administered intravenously, both Group 1
and 2 RMs of this study were challenged with an intrarectal
marginal infectious dose of SIVmac239. It has been previously
shown that Ig tissue distribution is slow and determined by the
rate and extent of blood perfusion into the target tissue. In fact,
Schneider et al. used fluorescent Abs to determine Ig anatomical
distribution after infusion in non-human primates (50). In that
study, the authors collected plasma, tissue biopsies and mucosal
secretions up to eight weeks following the administration of
these Abs. Interestingly, Ab levels in plasma peaked after 24 h,
but sequential biopsies showed Ab loading in the vaginal and
rectal mucosa up to one week after infusion. Accordingly, the
Env-specific Abs in our Group 1 vaccinees would likely not
have perfused the rectal mucosa at stable levels until 72 h after
infusion, two days after the first SIV challenge. Conversely,
Alter et al. recently published a study where they protected
naïve RMs after an intravenous infusion of vaccine-induced
non-neutralizing Abs, at a dose of 100 mg/kg, one day before
intrarectal SIVmac251 challenge (5). Thus, it is possible that
a particular functional profile and concentration of non-
neutralizing Abs in the target tissue is needed to protect against
intrarectal SIV challenge.
In summary, we investigated the role of non-neutralizing Abs
in the prevention and control of SIVmac239 replication. To do
this, we developed two methodologies to isolate and deplete
circulating Abs from RM sera, and transferred the isolated total
Ig from our rapid controllers to another group of vaccinated
RMs.While we detected low levels of transient viremia in the two
Mamu-B∗17+ RMs, additional studies with greater levels of Ig
depletion might be necessary to elucidate the true contribution of
non-neutralizing Abs to viremic suppression in elite controllers.
In our passive transfer study, we did not prevent SIVmac239
acquisition, even after delivering large amounts of purified Ig.
Interestingly, while gag-vaccinated RMs effectively reduce peak,
but not chronic phase viral loads, the administration of Env-
binding Abs to these animals significantly reduced chronic phase
viremia. Together, our data indicate that Env-binding Abs can
potentially contribute to control SIVmac239 replication in vivo,
independently of MHC-I genotype. However, larger monkey
studies will be needed to validate this hypothesis.
MATERIALS AND METHODS
Animal Experiments
The 14 Indian RMs (Macaca mulatta) used in this study were
housed at the Wisconsin National Primate Research Center
(WNPRC). All animals were cared for in accordance with
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Weatherall report guidelines and the recommendations included
in the National Research Council Guide for the Care and Use
of Laboratory Animals. All procedures were approved by the
University of Wisconsin Graduate School Animal Care and Use
Committee (animal welfare assurance number 16-00239 [A3368-
01]; protocol number G005248). RMs were separated as follows:
Group 1 (Ig-infused vaccinated RMs, n = 6), Group 2 (controls,
n = 6), and Group 3 (Mamu-B∗17 rapid controllers, n =
2). Purified Ig was prepared in saline bags and administered
intravenously into each animal. The rhesus IgG1 chimeric
version of Rozanolixizumab, Anti-FcRn Ab [RozR1LALA], was
engineered and produced by the nonhuman primate reagent
resource (NIH Nonhuman Primate Reagent Resource Cat# PR-
00-1, RRID: AB_2888630). Anti-FcRn Ab, which was infused
in Group 3 animals, was initially administered intravenously,
followed by a subcutaneous daily dose for a week in one of
the Group 3 RMs. We collected plasma and serum at the
indicated time points to measure viremia, total Ig and Env-
specific Ab levels.
Multiplex gp140-Specific Ig Subclass and
Fc Binding Affinity Assay
To determine the relative concentrations of total IgG, IgG1,
IgG2, IgG3, IgG4, and IgM in the sera of the Mamu-B∗17+
RMs at the time of the first SIV intrarectal challenge, we
first coupled SIVmac239 gp140 to magnetic beads (Luminex
Corporation) using NHS-ester linkages with Sulfo-NHS and
EDC (Thermo Fisher). Next, we incubated SIVmac239 gp140-
conjugated magnetic beads with diluted serum overnight at 4◦C
on a shaker. The following day, plates were spun down and
washed before adding these reagents to the appropriate wells:
mouse anti-monkey IgG PE (SouthernBiotech, #4700-09), to
determine total IgG, mouse anti-rhesus Ig (rhIg) G1 (NHPRR,
clone 7H11), rhIgG2 (NHPRR, clone 3C10), rhIgG3 (NHPRR,
clone 2G11), rhIgG4 (NHPRR, clone 7A8), and rhIgM (Life
Diagnostics, #2C11-1-5), to define the relative concentration of
each isotype, or PE-conjugated FcγRIIa, FcγRIIb, and FcγRIIIa
(R&D Systems, #1330-CD-050, #1875-CD-050, #4325-FC-050,
respectively). The plates were incubated for 1 h at room
temperature on a shaker. Next, we added goat anti-mouse IgG
Fc PE (Invitrogen, #31861) to the corresponding “isotype” wells
and incubated the plates for 1 h at room temperature on a shaker.
After washing all plates, fluorescence was quantified using an
IQue 3 flow cytometer (Intellicyt) and analysis was performed
using IntelliCyt ForeCyt (v8.1).
Antibody-Dependent Cellular Phagocytosis
A THP-1 phagocytosis assay was performed using SIVmac239
gp140-coated yellow/green fluorescent-neutravidin beads
(Molecular Probes Inc, #F8776), as previously described (51).
First, the fluorescent beads were incubated with diluted plasma
for 2 h at 37◦C. Following this incubation, THP-1 cells were
added to the plates and incubated at 37◦C overnight to allow
phagocytosis. The next day, cells were fixed and acquired using a
LSRII flow cytometer (BD Biosciences). Pooled plasma samples
were first titrated and then individually tested at a final dilution
of 1:500. We calculated the phagocytic scores as the geometric
mean fluorescent intensity (MFI) of the FITC-fluorescent beads
multiplied by the bead uptake percentage.
Antibody-Dependent Complement
Deposition
ADCD was assessed by monitoring C3b complement deposition
using SIVmac239 gp140-coated red fluorescent neutravidin
beads (Molecular Probes Inc, #F8775). Beads were first
incubated with diluted plasma for 2 h at 37◦C. After washing
the bead/plasma mixture, we added guinea pig complement
(Cedarlane Laboratories, #CL4051), diluted in gelatin veronal
buffer with calcium and magnesium (Boston Bioproducts),
and incubated the plates for 20min at 37◦C. Following this
incubation, all wells were washed with cold 15mM EDTA, then
incubated with FITC-conjugated goat anti-guinea pig C3 Ab (MP
Biomedicals, #855385) for 15min at room temperature. Last, the
plates were washed, and beads were resuspended in PBS. Samples
were acquired using a LSRII flow cytometer (BD Biosciences).
Percentage of complement deposition was determined by the
geometric MFI multiplied by the percentage of beads positive for
C3b deposition.
Antibody-Dependent NK Cell Activation
Plates were coated with SIVmac239 gp140 and incubated
overnight at 4◦C. All coated wells were washed and blocked with
5% BSA in PBS for 1 h at 37◦C. Plates were then washed and
diluted plasma samples were added into the corresponding wells
for 1 h at 37◦C. Simultaneously, CD107a PECy5 (BDBiosciences,
#555802), brefeldin A (Sigma, #B7651), and GolgiStop (BD
Biosciences, #554724) were incubated with human NK cell
culture for 2 h. After both incubations were completed, we
added the stimulated NK cells to the plates (50,000 cells
per well), and incubated them for 5 h at 37◦C. Next, NK
cells were transferred to V-bottom plates containing CD56
PE Cy7 (BD Biosciences, # 557747), CD16 APC Cy7 (BD
Biosciences, #55775), and CD3 Alexa Fluor 700 (BD Biosciences,
#557943) and incubated for 15min at room temperature. Plates
were then washed and resuspended in PBS. Samples were
acquired using a LSRII (BD Biosciences). Human NK cells were
isolated using a RossetteSep NK cell enrichment kit (StemCell
Technologies, #15065). NK cells were defined as CD3−/CD16+
and/or CD56+. Ab-dependent NK degranulation was calculated
as the percentage of NK cells positive for CD107a.
Anti-Env Antibody Enzyme-Linked
Immunosorbent Assay (ELISA)
The characterization and in vivo half-life of the purified Ig
isolated from theMamu-B∗17+ RMs were determined by ELISA.
ELISA plates were coated with either purified mouse anti-human
Ig (BD Biosciences, #555784) or purified SIVmac239 gp140
(Immune Technologies, #IT-001-140p) at 1µg/ml and incubated
overnight at 4◦C. The next day, all plates were washed with 1×
PBS-Tween20 and blocked with 5% powdered milk in PBS at
37◦C for 1 h. Following this incubation, the plates were washed
and 100 µl of serially diluted serum samples or purified Mamu-
B∗17-derived total Ig was added to the corresponding wells for
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1 h at 37◦C. After washing the plates, 100 µl of diluted goat anti-
human IgG-HRP Ab (SouthernBiotech, #2045-05) was added to
all wells and incubated for 1 h at 37◦C. The plates were washed





(EMD Millipore, #613544-100ML). Shortly after, the reaction
was stopped with TMB stop solution (SouthernBiotech, #0412-
01) and all plates were read at 450 nm on an Epoch microplate
reader (Biotek).
SIVmac239 Neutralization Assays
We assessed the SIVmac239 neutralization activity of the
purified Ig and sera of the Ig-infused RMs using a previously
described assay (52). Replication-competent SIVmac239 was
produced by transfecting HEK293T cells with the plasmid
using JetPrime (Polyplus transfection, #114-01). Seventy-
two hours later, supernatant was harvested and stored
at −80◦C. Purified Ig and RM sera were incubated with
SIVmac239 for 1 h at 37◦C before being transferred onto
TZM-bl cells (NIH AIDS Reagent program, #8129). After 48 h,
neutralization activity was calculated based on the luminescence
measurements of each duplicate well using the Bright-Glo
luciferase assay (Promega, #E2620).
Vaccination
The Group 1 RMs were vaccinated with genes encoding
SIVmac239 gag, nef, tat, rev, vif, vpr, and vpx using a rVSV prime
followed by a rAd5 boost. The rVSV prime consisted of three
plasmids containing the full-length Gag polyprotein (VSV-Gag1-
Gnj6), Nef protein (VSV-Nef1-Gnj6), or Tat-Rev fusion protein
(VSV-Tat-Rev1-Gnj6). Profectus Bioscience manufactured these
vectors. EachGroup 1 animal received an intramuscular injection
containing 1 × 108 PFU of each VSV vector. Six weeks later, the
Group 1 RMs were infused with three rAd5 vectors produced by
ViraQuest. These vectors encoded gag (rAd5-Gag), nef (rAd5-
Nef), or a fusion of vif-vpx-vpr-tat-rev genes. Each animal
received an intramuscular injection containing 1x1011 PFU of
each Ad5 vector.
Intracellular Cytokine Staining
PBMCs from Group 1 RMs at the time of the first SIV challenge
were stimulated with Gag, Nef and Tat peptides in R10 (RPMI,
10% FBS, 1× Pen/Strep/Amphotericin B) media containing anti-
CD28 and CD49d costimulatory Abs (BD Biosciences), as well
as a PE-conjugated anti-CD107a Ab (BioLegend), for 1 h at 37◦C
in a 5% CO2 incubator. Following this incubation, brefeldin A
(Sigma, #B7651), and GolgiStop (BD Biosciences, #554724) were
added to inhibit protein transport. All tubes were incubated for
eight additional hours at 37◦C. The antigenic stimuli used for
ICS consisted of pools of overlapping 15-mer peptides covering
the entire open reading frames (ORFs) of SIVmac239 Gag, Tat
and Nef at a final concentration of 1µM. The following day,
PBMCs were washed prior to adding the surface staining Ab
cocktail. This cocktail included ARD Aqua (live/dead viability
dye) and Abs against: CD4, CD8, CD14, CD16, CD20. Next, the
cells were fixed and permeabilized using the Cytofix/cytoperm
fixation/permeabilization solution kit (BD Biosciences, #554714).
After permeabilization, PBMCs were incubated with Abs against
CD3, IFN-γ, TNF-α, and CD69 for 1 h at room temperature.
Last, the cells were washed and acquired using a FACSAria II
(BD Biosciences). We analyzed the data using FlowJo 10.6 by
gating on live CD14−/CD16−/CD20−/CD3+ lymphocytes and
on cells expressing either CD4 or CD8, but not both markers.
Next, we gated cells positive for IFN-γ, TNF-α, or CD107a to
determine if they were co-expressed with CD69, a marker of
recent lymphocyte activation. We utilized the Boolean gate to
analyze all possible combinations. Leukocyte activation cocktail-
stimulated PBMCs were stained and used as a positive control.
SIV Challenge
The challenge stock used in this study was produced by the
Virology Services Unit of the WNPRC using SIVmac239 hemi-
genome plasmids obtained from the NIH AIDS Research and
Reference Reagents Program. Plasmids were transfected into
293T cells. Supernatant containing SIVmac239 virions was
harvested and propagated on mitogen-activated rhesus PBMCs.
Several healthy SIV negative rhesus macaques were used as
donors. The titer of the stock utilized was 90,000 50% tissue
culture infective doses (TCID50) per ml. All Mamu-A
∗01+ and
Mamu-A∗02+ animals were intrarectally challenged with 200
TCID50 (4.8 × 10
5 vRNA copies) of SIVmac239, as previously
described (27). Each challenge occurred every 2 weeks. Plasma
samples were taken at 7 and 10 days after exposure to determine if
an animal had become infected. Once an animal was SIV positive,
it was no longer challenged.
SIV Viral Load Measurements
SIV RNA viral load measurements were based on a previously
published protocol (53). Total RNA was extracted from 0.5ml
of EDTA-anticoagulated Indian RM plasma using QIAgen DSP
virus/pathogen Midi kits on a QIASymphony SP instrument.
A two-step RT-PCR reaction using random hexamers was
completed for each of the six replicates per sample, followed by
45 PCR cycles. The limit of detection in 0.5ml of plasma was 15
vRNA copies/ml. The primers and probe used for this procedure
were: forward primer, SGAG21, 5′GTCTGCGTCAT(dP)TGGT
GCATTC 3′; reverse primer SGAG22, 5′CACTAG(dK)TGTCTC
TGCACTAT(dP)TGTTTTG3′; probe, PSGAG23, 5′FAM-CTTC
(dP)TCAGT(dK)TGTTTCACTTTCTCTTCTGCG-BHQ1 3′.
Statistics
Differences between the Mamu-B∗17+ rapid controllers and
non-controllers at day of challenge, as well as viral loads of the
Group 1 RMs, were determined using Mann-Whitney U test.
Kaplan-Meier survival analysis was used to determine if the
SIVmac239 acquisition rate differed between both groups. A 0.05
significance threshold was utilized for each test.
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